Mr. Hogan: Sigma-Aldrich is a global leader in life science and high–technology. The company does 75% of its business in the life sciences and the remaining 25% in high technology applications. We are truly global with physical operations in 33 countries and sales into over 160 countries worldwide. Our business is broken into four segments, two of which serve the research market directly. The first of these is Scientific Research, a division that contributes a little over half the company’s sales and sells into universities, government research institutions, pharmaceutical, biotechnology and diagnostic companies and the chemical and allied products industry. Our second division that’s research-oriented is our Biotechnology division. That’s about one-fifth of the company. And it sells into those same markets, but its emphasis is strongly in molecular biology, synthetic DNA, cell culture, immuno chemistry and related products. Our third business is Fine Chemicals which sells many of the same products in much larger quantities generally for use in a variety of manufacturing applications. It too is about one-fifth of the company. And it sells primarily to chemical, pharmaceutical, biotech and other high–technology companies. The Fine Chemicals business also does custom synthesis work for the pharma and the biotech industries. Those three businesses together represent the broadest chemical manufacturing capabilities of any company we’re aware of worldwide. By broadest, I mean we have the ability to produce more chemistries at more temperatures in more physical locations. In fact, we make about 40,000 different chemical compounds. In total, we offer about 85,000 different products, including those we in-source. We have access to another 250,000 compounds through a sophisticated and proprietary sourcing system called CHESS. Our fourth and final division, which is the smallest unit of Sigma-Aldrich, is our Diagnostics division. At 70 million, it represents about 7% of our sales and sells largely to hospitals, physicians and commercial laboratories. It specializes in niche markets for cardiac, point of care, immunoassay and coagulation. So those are our four major businesses. In total, we’re roughly 1.1 billion in size.
Tickers included in this excerpt: SIAL
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.